Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors

Next Previous
Trial Profile

An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CX 2051 (Primary)
  • Indications Colorectal cancer; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors CytomX Therapeutics

Most Recent Events

  • 12 May 2025 Interim results presented in the CytomX Therapeutics Media Release.
  • 12 May 2025 According to a CytomX Therapeutics media release, Phase 1 dose expansions has been initiated at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses. Phase 1 data update in advanced CRC in at least 70 patients is expected to be presented by Q1 2026.
  • 06 Jan 2025 According to a CytomX Therapeutics media release, The Phase 1 study of CX-904 has enrolled over 70 patients to date. The 15 mg target step-dose level has been cleared and the maximum tolerated dose has not been reached and enrollment in 2025 will prioritize escalation to higher dose levels.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top